ArticleBMC medicine2025

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions.

Yang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.